Dapsone Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Dapsone Supply and Access in 2026

If you prescribe Dapsone — whether for dermatitis herpetiformis, leprosy, bullous pemphigoid, or off-label indications — you've likely fielded calls from patients struggling to fill their prescriptions. While Dapsone is not formally listed on the FDA Drug Shortage database as of early 2026, the practical reality is that many patients face recurring difficulty obtaining this medication.

This briefing provides an overview of the current Dapsone supply landscape, prescribing considerations, cost and access data, and tools you can use to support your patients.

Timeline: How We Got Here

Dapsone has been a cornerstone of therapy for Hansen's disease and dermatitis herpetiformis since the mid-20th century. Unlike most generic medications that attract multiple manufacturers over time, oral Dapsone has remained a low-volume, niche product:

• 1950s-1980s: Dapsone becomes standard therapy for leprosy (in WHO multidrug regimens) and the treatment of choice for dermatitis herpetiformis
• 1990s-2010s: Off-label use expands significantly — bullous pemphigoid, ITP, linear IgA disease, PCP prophylaxis in HIV patients, vasculitis, and other neutrophilic dermatoses
• 2010s-present: Manufacturer consolidation leaves Jacobus Pharmaceutical as the dominant U.S. supplier of oral Dapsone tablets. Generic competition remains minimal due to low market size
• 2024-2026: Patients report increasing difficulty filling prescriptions, driven by limited production capacity, pharmacy stocking practices, and distribution inefficiencies

Prescribing Implications

Monitoring Requirements Remain Critical

Regardless of availability challenges, Dapsone's safety profile demands careful monitoring:

• Baseline: CBC with differential, reticulocyte count, G6PD level, hepatic function panel, methemoglobin level
• Ongoing: CBC weekly for the first month, then monthly for 6 months, then semiannually. Liver function tests periodically. Methemoglobin levels if symptoms arise
• G6PD testing is essential: G6PD-deficient patients face significantly elevated risk of severe hemolytic anemia. Screen all patients before initiating therapy

Key Drug Interactions to Document

When prescribing Dapsone in combination with other agents, be aware of clinically significant interactions:

• Trimethoprim: Increases Dapsone levels and methemoglobinemia risk. Monitor closely if co-prescribed
• Rifampin: Decreases Dapsone levels via CYP3A4 induction. Used together in leprosy regimens, but efficacy for other indications may be compromised
• Folic acid antagonists (Methotrexate, Pyrimethamine): Additive hematologic toxicity risk
• Probenecid: Reduces Dapsone clearance, potentially increasing toxicity

For a comprehensive review, see our resource on Dapsone drug interactions.

Current Availability Picture

The key facts providers should understand about Dapsone supply in 2026:

• FDA status: Not currently listed as a drug shortage
• Manufacturing: Very few manufacturers produce oral Dapsone tablets. Jacobus Pharmaceutical remains the primary U.S. source
• Pharmacy stocking: Most chain pharmacies do not routinely stock oral Dapsone. It is typically ordered on demand, with 1-3 business day fulfillment when available from distributors
• Localized disruptions: Intermittent regional stock-outs occur, creating unpredictable gaps in patient access
• Topical formulations: Aczone (topical Dapsone 5% and 7.5% gel) is available in generic form for acne but is not interchangeable with oral Dapsone for systemic conditions

Cost and Access Considerations

Understanding the cost landscape helps when counseling patients:

• Generic oral Dapsone 100 mg, 30 tablets: Cash price ranges from $29-$114 depending on pharmacy
• With discount cards (GoodRx, SingleCare): As low as $29-$45 for 30 tablets
• PruGen Solutions program: $25/Rx for insured patients, $75/Rx for uninsured ($150/90-day), with free home delivery. Enrollment requires prescriber participation — call 844-436-7928
• Insurance coverage: Generic oral Dapsone is generally covered by commercial plans with low copays. Some Medicare Part D plans may not cover it. Prior authorization is rarely required for FDA-approved indications but may be needed for off-label use

For patient savings guidance, refer patients to our resource on saving money on Dapsone.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps patients and providers check real-time pharmacy stock for Dapsone and other hard-to-find medications. Consider recommending it to patients during visits, or having your staff use it to identify stocking pharmacies before writing prescriptions.

PruGen Solutions Enrollment

The PruGen Solutions program requires prescriber enrollment but provides a reliable supply channel with home delivery. This can be particularly valuable for patients in areas with limited pharmacy access.

Prescriber Tips

• When initiating Dapsone, confirm pharmacy stock before the patient leaves your office
• Consider writing for 90-day supplies to reduce refill frequency and stock-out risk
• Document off-label rationale thoroughly to support any prior authorization requirements
• Maintain a list of local pharmacies that reliably stock Dapsone — share this with patients

Looking Ahead

The fundamental challenge with Dapsone — limited manufacturing for a small market — is unlikely to resolve quickly. No new manufacturers have announced plans to enter the market, and production incentives for low-volume generic drugs remain weak under current regulatory and economic conditions.

Providers can mitigate the impact on their patients by staying informed about supply dynamics, proactively verifying availability, enrolling eligible patients in assistance programs, and maintaining familiarity with therapeutic alternatives.

Final Thoughts

Dapsone remains an irreplaceable medication for many patients. The availability challenges in 2026 are real but manageable with proactive prescribing practices and the right tools. By incorporating stock verification, home delivery programs, and alternative planning into your workflow, you can help ensure your patients maintain access to this essential therapy.

Visit medfinder.com/providers for provider-specific tools and resources.